Table 1 Eligibility criteria for inclusion into the systematic review
PICO | Inclusion criteria | Exclusion criteria |
|---|---|---|
Population | - Either adults or children - Diagnosed with STS, including any of the following histologies: - Liposarcoma - Leiomyosarcoma - Undifferentiated pleomorphic sarcoma - Synovial sarcoma - Malignant peripheral nerve sheath tumor and triton tumor - Alveolar soft part sarcoma - Desmoid tumor - Solitary fibrous tumor/hemangiopericytoma - Fibrosarcoma or variants - Vascular sarcoma - Epithelioid sarcoma - Clear cell sarcoma - Desmoplastic small round cell tumor - Extraskeletal myxoid chondrosarcoma - Endometrial stromal sarcoma - Extraskeletal osteogenic sarcoma - Other STS not listed in the inclusion list - Diagnosis of bone sarcoma, including any of the following histologies: - Osteosarcoma - Chondrosarcoma - Ewing’s sarcoma - Rhabdomyosarcoma - Articles published up to March 31, 2019 - Articles published that incorporates either a comparison of, or independent listing of populations outlined within intervention and/or comparison group. | - Sarcomatoid epithelial tumors - Gastrointestinal stromal tumors |
Intervention | - Studies including subjects who underwent pulmonary, hepatic, or other sites of metastasectomy for recurrent or de novo STS | Patients who underwent palliative surgery for symptomatic purposes without complete resection of metastasis (e.g., divert colostomy). |
Outcomes | - Studies including survival measurement of either a comparison, or individual listing, of intervention and/or comparison group. - Secondary outcomes include 30-day post-operative mortality, recurrence free survival, time off of systemic therapy, and patient-reported outcomes including quality of life end points where available. | Studies that do not include mortality post metastasectomy as a study outcome |